DrugPatentWatch Database Preview
B Braun Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for B BRAUN, and what generic alternatives to B BRAUN drugs are available?
B BRAUN has one hundred and twelve approved drugs.
There are two US patents protecting B BRAUN drugs.
There are twenty-four patent family members on B BRAUN drugs in twenty-five countries and one hundred and ninety supplementary protection certificates in sixteen countries.
Summary for B Braun
| International Patents: | 24 |
| US Patents: | 2 |
| Tradenames: | 221 |
| Ingredients: | 59 |
| NDAs: | 112 |
Drugs and US Patents for B Braun
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B Braun | CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER | ceftriaxone sodium | INJECTABLE;INJECTION | 050796-001 | Apr 20, 2005 | AP | RX | Yes | Yes | Start Trial | Start Trial | ||||
| B Braun | MANNITOL 5% IN PLASTIC CONTAINER | mannitol | INJECTABLE;INJECTION | 020006-001 | Jul 26, 1993 | AP | RX | No | No | Start Trial | Start Trial | ||||
| B Braun | DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER | dextrose; potassium chloride; sodium chloride | INJECTABLE;INJECTION | 018268-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
| B Braun | DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | dextrose; sodium chloride | INJECTABLE;INJECTION | 018047-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
| B Braun Medical Inc | BUPIVACAINE HYDROCHLORIDE | bupivacaine hydrochloride | INJECTABLE;SPINAL | 209087-001 | Apr 2, 2019 | AP | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for B Braun
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| B Braun | HEPATAMINE 8% | amino acids | INJECTABLE;INJECTION | 018676-001 | Aug 3, 1982 | 3,950,529 | Start Trial |
| B Braun | UCEPHAN | sodium benzoate; sodium phenylacetate | SOLUTION;ORAL | 019530-001 | Dec 23, 1987 | 4,284,647 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for B Braun Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Italy | MI20122120 | Start Trial |
| South Korea | 20150085131 | Start Trial |
| Ukraine | 115078 | Start Trial |
| China | 105283222 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2007028788 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for B Braun Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0748228 | 11C0002 | France | Start Trial | PRODUCT NAME: MANNITOL; NAT. REGISTRATION NO/DATE: NL 34557 20080819; FIRST REGISTRATION: SE - 22708 20061020 |
| 1318980 | C 2015 053 | Romania | Start Trial | PRODUCT NAME: PANOBINOSTAT SAU O SARE ACCEPTABILA FARMACEUTIC SAU UNDERIVAT AL ACESTUIAN-HIDROXI-3-[-[4-({[2-(2-METIL-1H-INDOL-3-IL)ETIL}AMINO}METIL)FENIL]]-2E-2-PROPENAMIDA; NATIONAL AUTHORISATION NUMBER: EU/1/15/1023/001, EU/1/15/1023/002, EU/1/15/1023/003, EU/1/15/1023/004, EU/1/15/1023/005, EU/1/15/1023/006, EU/1/15/1023/007, EU/1/15/1023/008, EU/1/15/1023/009; DATE OF NATIONAL AUTHORISATION: 20150828; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1023/001, EU/1/15/1023/002, EU/1/15/1023/003, EU/1/15/1023/004, EU/1/15/1023/005, EU/1/15/1023/006, EU/1/15/1023/007, EU/1/15/1023/008, EU/1/15/1023/009; DATE OF FIRST AUTHORISATION IN EEA: 20150828 |
| 0306228 | SPC/GB01/002 | United Kingdom | Start Trial | PRODUCT NAME: 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE, "ROSIGLITAZONE" ITS TAUTOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS, SUCH AS THE MALEATE, AND PHARMACEUTICALLY ACCEPTABLE SOLVATES.; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711 |
| 1532149 | 92128 | Luxembourg | Start Trial | PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE |
| 2603514 | CA 2019 00015 | Denmark | Start Trial | PRODUCT NAME: EN KOMBINATION AF VABORBACTAM, OG/ELLER ET SALT OG/ELLER HYDRAT DERAF, OG MEROPENEM, OG/ELLER ET SALT OG/ELLER HYDRAT DERAF, SAERLIGT MEROPENEM TRIHYDRAT; REG. NO/DATE: EU/1/18/1334 20181122 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
